New Data Validates Veracyte’s Test for Thyroid Cancer Treatment Guidance
Genomic Diagnostics company Veracyte says new data demonstrates the clinical and analytical validity of its Afirma Xpression Atlas (XA) genomic test, which was developed to...
Myriad Partners with LCPMH to Assess Clinical Utility of Prolaris Prostate Cancer Test
Myriad Genetics said today it will assess the clinical utility of its Prolaris test in men diagnosed with prostate cancer, through a collaboration with the...
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
AI Improves Differentiation of Head and Neck Cancers
Diagnosing head and neck cancers is challenging. It is particularly difficult to distinguish pulmonary metastases of head and neck squamous cell carcinoma (HNSC) from primary...
Going Deeper into Long Reads: Oxford Nanopore Licenses CRISPR-Cas9 IP from Caribou
The British sequencing company famous for producing ultra-long reads, Oxford Nanopore Technologies announced today that have entered into a non-exclusive license agreement with Caribou...
Actionable Type 2 Diabetes Risks Uncovered
More than 67 actionable clinical discoveries were made through deep longitudinal genomic analysis by a group led by Michael Snyder, MD, chair of the...
CRISPR-Chip Product, Genome Sensor, Launched as Cardea, Nanosens Merge
The CRISPR-Chip garnered much attention earlier this year when the novel graphene-based biosensor CRISPR-Cas technology was introduced in a Nature Biomedical Engineering publication in March....
Interpace Diagnostics, Genecast Join Forces for Translational Studies, Clinical Trials Services
Personalized medicine company Interpace Diagnostics announced that it has entered into a partnership to jointly develop, promote, and offer translational studies and clinical trial...
Celsee, IncellDx Sign Lung Cancer CTC PD-L1 Agreement
The companies will co-commercialize their respective single-cell technologies for CTCs and PD-L1 expression following positive study results
![Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1907-218x150.jpeg "LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy")
LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy
Bringing it closer to one of the world’s fastest-growing diagnostic market places, the Laboratory for Advanced Medicine (LAM)’s blood-based liver cancer test has been...
